Nicotinamide Mononucleotide (NMN, CAS 1094-61-7, C11H15N2O8P, MW 334.22 g/mol) is a naturally occurring nucleotide and the most direct NAD+ precursor in human biology. NMN converts to NAD+ in a single enzymatic step via NMNAT (Nicotinamide Mononucleotide Adenylyltransferase) — the rate-limiting reaction in NAD+ biosynthesis. Unlike NR which requires three enzymatic steps (NRK1/2 then NMNAT), NMN is one step away from active NAD+. A landmark 2019 Nature Metabolism study identified the Slc12a8 transporter — a specific membrane protein that transports NMN directly into cells throughout the body (intestine, liver, pancreas, brain), confirming a dedicated cellular uptake mechanism. Once inside, NMN-derived NAD+ activates the sirtuin cascade (SIRT1–7) — the master longevity regulators governing DNA repair, mitochondrial biogenesis, oxidative stress defense, and cellular senescence — directly reversing the age-related decline in NAD+ that is a hallmark of aging. NMN also supports PARP enzymes for DNA damage repair. UPOR Biotech’s NMN is produced via enzymatic biosynthesis (fermentation), yielding a molecule bioidentical to endogenous human NMN with 98%+ purity.

Clinical trials have demonstrated multiple significant benefits of NMN supplementation in humans: (1) Increased NAD+ levels — a 2021 randomized, double-blind, placebo-controlled trial (n=30) showed NMN (250 mg/day) significantly increased whole-blood NAD+ levels without adverse effects. (2) Improved insulin sensitivity — a 2021 study (n=25 postmenopausal women with prediabetes) demonstrated NMN (250 mg/day for 10 weeks) improved muscle insulin sensitivity by 25% and insulin signaling via the Akt/mTOR pathway. (3) Enhanced physical performance — a 2021 study (n=48 healthy runners) showed NMN (300–1200 mg/day for 6 weeks) improved aerobic capacity (VO2 max), ventilatory threshold, and oxygen utilization in skeletal muscle. (4) Improved sleep quality and reduced drowsiness with better gait speed in older adults (2022 clinical trial). (5) Preclinical models consistently demonstrate NMN extends healthspan, reverses vascular aging, improves cognitive function, enhances DNA repair, and protects against metabolic dysfunction — all mediated through NAD+/sirtuin/PARP pathways. Harvard geneticist Dr. David Sinclair’s laboratory has been at the forefront of NMN longevity research for over a decade, establishing NMN as the most scientifically credible NAD+ precursor available.

The clinically validated NMN dosage range is 250–500 mg/day orally for healthy adults, with some research protocols extending to 900–1200 mg/day for athletic performance. Sublingual administration bypasses first-pass metabolism and provides superior bioavailability compared to standard oral capsules — hold powder under the tongue for 30–60 seconds. NMN is stable in the acidic stomach environment and is absorbed in the small intestine, with cellular uptake mediated by the Slc12a8 transporter widely expressed in the intestine, liver, pancreas, and brain. Best practices: take NMN in the morning to align with circadian NAD+ rhythms, with or without food (clinical trials have used both successfully). For optimal anti-aging protocols, combine NMN with a sirtuin activator (resveratrol or pterostilbene) and TMG (trimethylglycine) as a methyl donor — the Sinclair longevity stack. NMN is well-tolerated with no serious adverse events reported across all published human trials. Liposomal NMN formulations offer enhanced bioavailability for premium product positioning. Always store NMN at -20C for long-term stability and protect from moisture.

NMN, NR, and NAD+ sit at different levels of the NAD+ biosynthesis hierarchy — they are not interchangeable. NAD+ (Nicotinamide Adenine Dinucleotide) is the essential coenzyme required by all cells, but direct oral NAD+ has extremely poor bioavailability — rapidly degraded by gut enzymes and unable to cross cell membranes without first being broken down into precursors. NR (Nicotinamide Riboside) is a bacterial/yeast-derived precursor requiring three enzymatic steps to reach NAD+: NR NMN (via NRK1/NRK2 kinases) NMN NAD+ (via NMNAT). NR lacks a dedicated mammalian transporter and NRK expression is tissue-limited, particularly in muscle and brain. NMN (Nicotinamide Mononucleotide) is the endogenous mammalian nucleotide — it converts to NAD+ in a single step via NMNAT and possesses the Slc12a8 transporter (discovered 2019) for direct cellular uptake without prior dephosphorylation. NMN is naturally present in human foods (edamame: 0.47–1.88 mg/100g, broccoli, avocado, cucumber, tomato) and in breast milk, confirming its physiological dietary role. For formulators and brands: NMN offers the most direct NAD+ boost, strongest clinical evidence base, and most differentiated commercial positioning — making it the premium tier in the NAD+ precursor market.

Every NMN shipment includes comprehensive documentation: COA (HPLC purity 99.0% nutraceutical or 98.0% cosmetic, full impurity profile, heavy metals 10 ppm with Pb 2 ppm / As 1 ppm / Hg 1 ppm / Cd 1 ppm, residual solvents per USP 467 / ICH Q3C, microbial panel per USP 61/62 and EP, endotoxins per USP 85), MSDS, HPLC Chromatogram (signed and dated), IR Spectrum confirming -Nicotinamide Mononucleotide structure, NMR Spectrum (1H and 13C) confirming -configuration and anomeric purity, Certificate of Origin (China), ISO 9001:2015 Certificate, ISO 22000 Certificate, HACCP Certificate, FDA Facility Registration, HALAL Certificate, KOSHER Certificate, Non-GMO Statement, Allergen Statement, Stability Data (real-time -20C and accelerated 25C/60%RH), Residual Solvents Statement, Elemental Impurities Statement (ICH Q3D), and Complete Lot Traceability from fermentation batch to finished powder. Free sample available for qualified B2B buyers. MOQ: 1 kg. All documents provided in English.